LRT Capital Management LLC Cuts Stock Position in Novo Nordisk A/S $NVO

LRT Capital Management LLC decreased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 70.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,234 shares of the company’s stock after selling 14,988 shares during the period. LRT Capital Management LLC’s holdings in Novo Nordisk A/S were worth $317,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in NVO. Franklin Resources Inc. increased its stake in Novo Nordisk A/S by 4,190.8% during the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock worth $776,016,000 after buying an additional 13,658,867 shares during the period. Capital International Investors increased its stake in Novo Nordisk A/S by 52.4% during the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after buying an additional 6,092,192 shares during the period. Boston Partners purchased a new stake in Novo Nordisk A/S during the 3rd quarter worth $310,199,000. Bank of Montreal Can increased its stake in Novo Nordisk A/S by 138.9% during the 4th quarter. Bank of Montreal Can now owns 2,525,827 shares of the company’s stock worth $128,514,000 after buying an additional 1,468,409 shares during the period. Finally, Clear Street Group Inc. purchased a new stake in Novo Nordisk A/S during the 3rd quarter worth $56,378,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: UK regulators approved Novo Nordisk’s daily Wegovy pill, making it the first GLP-1 weight-loss tablet approved in the UK. That expands the company’s obesity franchise beyond injections and could open a new growth channel. UK approves Novo weight-loss pill to edge open European market
• Positive Sentiment: Several follow-up reports highlighted the UK approval as a milestone that could help Novo regain momentum in the obesity market and broaden access to Wegovy through private prescriptions. Novo Nordisk Wegovy pill becomes first daily GLP-1 weight-loss pill approved in the UK
• Positive Sentiment: Analysts also raised FY2026 EPS estimates slightly, signaling still-solid earnings expectations despite recent share-price weakness. Novo Nordisk A/S Trading Down 0.1%
• Neutral Sentiment: Some commentary on the “Wegovy pill” said the approval is encouraging but not yet enough to make certain investors buy, suggesting the market may want more proof of commercial impact before re-rating the stock. Novo Nordisk: Wegovy Pill Is Encouraging But Still Not Enough To Make Me Buy
• Negative Sentiment: Novo Nordisk disclosed an IT security incident involving unauthorized access to internal systems and potential data copying, which could pressure investor confidence even though the company said operations were not materially affected. Novo Nordisk hit by cyber incident, probes data breach
• Negative Sentiment: Another report said some U.S. employers may drop GLP-1 obesity-drug coverage in 2027, a potential headwind for long-term demand and reimbursement for Wegovy and rival products. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

Novo Nordisk A/S Trading Down 0.1%

NYSE NVO opened at $43.90 on Friday. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $81.44. The company has a 50-day simple moving average of $42.28 and a 200-day simple moving average of $46.00. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The firm has a market capitalization of $196.02 billion, a PE ratio of 10.31, a price-to-earnings-growth ratio of 3.92 and a beta of 0.78.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The business had revenue of $10.85 billion during the quarter. On average, equities analysts forecast that Novo Nordisk A/S will post 3.45 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on NVO shares. Deutsche Bank Aktiengesellschaft downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, May 12th. Sanford C. Bernstein started coverage on shares of Novo Nordisk A/S in a research note on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price target on the stock. TD Cowen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price target on the stock. in a research note on Tuesday, March 10th. Finally, Nordea Equity Research downgraded shares of Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. Four investment analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.